Allakos Inc
NASDAQ:ALLK

Watchlist Manager
Allakos Inc Logo
Allakos Inc
NASDAQ:ALLK
Watchlist
Price: 0.8766 USD -3.34% Market Closed
Market Cap: 78.3m USD
Have any thoughts about
Allakos Inc?
Write Note

Allakos Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Allakos Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Allakos Inc
NASDAQ:ALLK
Cash from Operating Activities
-$105.4m
CAGR 3-Years
16%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$16.5B
CAGR 3-Years
-10%
CAGR 5-Years
4%
CAGR 10-Years
12%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$10B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$7.3B
CAGR 3-Years
-6%
CAGR 5-Years
-6%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
-$842.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.2B
CAGR 3-Years
-11%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Allakos Inc
Glance View

Market Cap
78.3m USD
Industry
Biotechnology

Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Redwood City, California and currently employs 192 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are widely distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company also developed a formulation of lirentelimab for subcutaneous (SC) administration. The firm is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.

ALLK Intrinsic Value
1.0378 USD
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Allakos Inc's Cash from Operating Activities?
Cash from Operating Activities
-105.4m USD

Based on the financial report for Sep 30, 2024, Allakos Inc's Cash from Operating Activities amounts to -105.4m USD.

What is Allakos Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-13%

Over the last year, the Cash from Operating Activities growth was 24%. The average annual Cash from Operating Activities growth rates for Allakos Inc have been 16% over the past three years , -13% over the past five years .

Back to Top